GlassScriptPhysician profile
Michele Capaccio
NPI 1841503463
$2,421.56
in general payments reported to CMS, 2019-2025
35 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $503 · 2022: $686 · 2023: $546 · 2024: $527 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,232.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $352.71 | 2022-2025 | |
| Eisai INC. | $152.49 | 2021-2024 | |
| Biogen, INC. | $151.50 | 2021-2024 | Vumerity, Plegridy |
| Amneal Pharmaceuticals LLC | $150.44 | 2021-2024 | Rytary |
| Lundbeck LLC | $128.70 | 2021-2024 | Vyepti |
| Neurelis, INC. | $100.65 | 2021-2023 | Valtoco |
| Emd Serono, INC. | $98.29 | 2022-2024 | Mavenclad |
| Takeda Pharmaceuticals U.S.A., INC. | $94.49 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $91.05 | 2022 | |
| Amylyx Pharmaceuticals, INC. | $89.62 | 2023-2024 | Relyvrio |
| Alexion Pharmaceuticals, INC. | $88.20 | 2021-2024 | Ultomiris |
| Biohaven Pharmaceuticals, INC. | $79.78 | 2021 | |
| Argenx US, INC. | $78.60 | 2022-2024 | Vyvgart Hytrulo |
| Genzyme Corporation | $77.56 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $69.55 | 2021-2024 | Dysport |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tanabe Pharma America, INC. | $67.89 | 2023-2024 | |
| Arbor Pharmaceuticals, INC. | $65.89 | 2021 | |
| Upsher-Smith Laboratories LLC | $54.45 | 2021-2023 | |
| Harmony Biosciences LLC | $54.30 | 2022 | |
| Lilly USA, LLC | $44.04 | 2021-2023 | Emgality, Reyvow |
| Boston Scientific Corporation | $42.34 | 2025 | Watchman Flx |
| Impel Pharmaceuticals INC. | $40.56 | 2023 | Trudhesa |
| Sumitomo Pharma America, INC. | $32.55 | 2023 | Aptiom |
| Ucb, INC. | $26.00 | 2024 | Rystiggo |
| Avanir Pharmaceuticals, INC. | $23.44 | 2022 | |
| Merck Sharp & Dohme LLC | $20.59 | 2021 | |
| Sk Life Science, INC. | $18.39 | 2023 | |
| Corium, LLC | $18.22 | 2022 | |
| Supernus Pharmaceuticals, INC. | $17.80 | 2022 | |
| Almatica Pharma LLC | $17.59 | 2023 | Gralise |
| Allergan, INC. | $17.15 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $15.82 | 2023 | Nuedexta |
| Scilex Pharmaceuticals INC. | $14.99 | 2024 | |
| Azurity Pharmaceuticals, INC. | $14.74 | 2024 | Horizant |
| Adlon Therapeutics L.P. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Capaccio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.